<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE GlossaryTerm >
<GlossaryTerm id="CDR0000559131"><TermName>tremelimumab</TermName><TermPronunciation>(treh-meh-LIM-yoo-mab)</TermPronunciation><TermDefinition><DefinitionText>A substance being studied in the treatment of some types of cancer. Tremelimumab binds to a protein called CTLA-4, which is found on the surface of T cells (a type of white blood cell). It may block CTLA-4 and help the immune system kill cancer cells. Tremelimumab is a type of monoclonal antibody and a type of immunomodulatory agent.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><MediaLink ref="CDR0000720429" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;tremelimumab&quot;" language="en" id="_5"/><MediaLink ref="CDR0000720428" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;tremelimumab&quot;" language="es" id="_6"/><SpanishTermName>tremelimumab</SpanishTermName><SpanishTermDefinition><DefinitionText>Sustancia en estudio para el tratamiento de ciertos tipos de cáncer. El tremelimumab se une a una proteína llamada CTLA-4,  que se encuentra en la superficie de las células T (tipo de glóbulo blanco). Podría impedir la acción de la CTLA-4, y ayudar al sistema inmunitario a eliminar las células cancerosas. El tremelimumab es un tipo de anticuerpo monoclonal y un tipo de inmunomodulador.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateFirstPublished>2008-03-10</DateFirstPublished><DateLastModified>2012-10-30</DateLastModified></GlossaryTerm>
